Publications: 490 in 2026-04. -2.5% share of all MeSH-indexed PubMed records vs the same month last year (515 in 2025-04).
PublicationsPubMed
4902026-04
-2.5% share of all MeSH-indexed PubMed records vs same month last year (515 in 2025-04)provisional · settling
0.45% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 53 in 2026-09. -28.4% vs the same month last year (74 in 2025-09).
Clinical trialsClinicalTrials.gov
532026-09
-28.4% vs same month last year (74 in 2025-09)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 60 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 60 is in the 66th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
602026-09
66th percentilein its typical range, versus 16-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 733 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 733 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
7332026-09
91st percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 39 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 39 is in the 94th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
392026-09
94th percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 490 is in the 70th percentile, running high, versus 320 months since 2000.
70thpercentile
running high
490/mo · higher than 70% of 320 months since 2000
Clinical trials
Clinical trials: latest count 53 is in the 90th percentile, running high, versus 317 months since 2000.
90thpercentile
running high
53/mo · higher than 89% of 317 months since 2000
NIH grantsprovisional
NIH grants: latest count 60 is in the 66th percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
66thpercentile
in its typical range
60/mo · higher than 63% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 733 is in the 91st percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
91stpercentile
near its historical high
733/mo · higher than 88% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 39 is in the 94th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
94thpercentile
near its historical high
39/mo · higher than 88% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 317 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 1,158/mo
Clinical trials2000 to 2026 · 317 mopeak 109/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 82/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 873/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 39/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-08..2026-07
6%of works have an industry affiliation
Chinese Academy of Medical Sciences & Peking Union Medical College533
The University of Texas MD Anderson Cancer Center471
2026-09-25biorxivDepartment of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei 106, Taiwan
Organizations only. No person data.
Would you read a monthly digest for Non-Small-Cell Lung Cancer?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Non-Small-Cell Lung Cancer. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Non-Small-Cell Lung Cancer.
How we map "Non-Small-Cell Lung Cancer"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Carcinoma, Non-Small-Cell Lung"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10
Author institutions (OpenAlex)
topic T10417, T10202; search 'non-small cell lung cancer NSCLC'
Clinical trials (ClinicalTrials.gov)
ConditionSearch: non-small cell lung cancer OR NSCLC OR non-small-cell lung carcinoma OR nonsmall cell lung cancer
NIH grants (RePORTER)
advanced_text_search: non-small cell lung cancer NSCLC